# A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

> **NCT01370811** · PHASE2 · COMPLETED · sponsor: **Orient Pharma Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Sialorrhoea

## Interventions

- **DRUG:** oxybutynin and clonidine oral solution treatment A
- **DRUG:** oxybutynin and clonidine oral solution treatment B
- **DRUG:** oxybutynin and clonidine oral solution treatment C
- **DRUG:** oxybutynin and clonidine oral solution treatment D

## Key facts

- **NCT ID:** NCT01370811
- **Lead sponsor:** Orient Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370811, "A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01370811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*